Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Verisante Technology Inc V.VER.H

Alternate Symbol(s):  VRSEF

Verisante Technology, Inc. is a Canada-based company. The Company does not operate any active business other than to identify and complete a reverse takeover (RTO) with a company in one of its target sectors that demonstrates significant growth potential and/or value creation opportunities for shareholders. The Company may pursue a target in any industry, it intends to focus its search on companies that meet its acquisition target characteristics within the life sciences sectors.


TSXV:VER.H - Post by User

Bullboard Posts
Post by firesIayer96on Oct 08, 2012 12:15pm
483 Views
Post# 20461930

Huge potential for Core cervical cancer screening

Huge potential for Core cervical cancer screening

Obviously management's current focus is getting the Aura out the door. Kicking at the Aura's heels is the Core/lung, with news on this expected by the end of the year. There has not been much discussion on the Core as a screening tool for colon or cervical cancer. Huang's recent work at NUS suggests that there is huge potential for the Core to detect cervical cancer with excellent statisticals.

Zhiwei Huang, Cervical, Sensitivity 93%, Specificity 97%.

https://www.bioeng.nus.edu.sg/optbioimaging/Huang/publication/2009_High%20wavenumber%20Raman%20spectroscopy%20for%20in%20vivo%20detection%20of%20cervical%20dysplasia.pdf

Bullboard Posts